There is an ongoing clinical trial to investigate the effectiveness of adjuvant endocrine therapy for operable ERβ positive, ERα/PR negative, HER-2 negative breast cancer (https://clinicaltrials.gov/ct2/show/NCT02089854). Here, ERBB2 is linked to breast carcinoma.